Repare Therapeutics Enters into Definitive Agreement to be Acquired …
Jun 30, 2025 · CAMBRIDGE, Mass. & MONTREAL -- (BUSINESS WIRE)--Nov. 14, 2025-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology …
Repare Therapeutics | Synthetic Lethality | Press Releases
Jan 16, 2026 · Press releases for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc ...
Jan 16, 2026 · Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes …
Repare Therapeutics | Precision Oncology | Investor Relations
Corporate Profile for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.
Repare Therapeutics | Precision Oncology | Repare Therapeutics ...
Oct 13, 2023 · Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to …
Repare Therapeutics Provides Corporate Update and Highlights ...
Jan 8, 2024 · Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to …
Repare Therapeutics Announces a Worldwide License and …
Jun 1, 2022 · Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to …
Repare Therapeutics Provides Business and Clinical Update and …
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
Repare Therapeutics Announces Positive Results of the Lunresertib and ...
Dec 12, 2024 · Repare plans to provide the final Phase 3 trial protocols for regulatory clearance imminently and intends to start the first Phase 3 Lunre+Camo trial in endometrial cancer in the …
Repare Therapeutics to Regain Global Rights to Camonsertib
Feb 12, 2024 · Repare expects to report additional camonsertib and lunresertib combination therapy data from the expansion cohorts of this trial in the second half of 2024. Repare has met all …